CureVac N.V. (CVAC)
After hours:
- ACCESSWIRE
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
- Simply Wall St.
What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...
- ACCESSWIRE
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
* Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer * Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigensTÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicine
